Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 International position paper on febuxostat.

Literature DB >> 20401506

International position paper on febuxostat.

Tim L Jansen¹, Pascal Richette, Fernando Perez-Ruiz, Anne-Kathrin Tausche, Philip-André Guerne, Leonardo Punzi, Burkhard Leeb, Victoria Barskova, Till Uhlig, José Pimentão, Irena Zimmermann-Górska, Elisio Pascual, Thomas Bardin, Michael Doherty.

Abstract

This position paper aims to clarify the presumed place of febuxostat in the management of gout patients. Since this novel xanthine oxidase inhibitor is now available, an international group of gout experts decided to formulate an international consensus statement. This statement presents the place for this new xanthine oxidase inhibitor in the treatment of gout which may contribute to optimize treatment of gout patients in Europe and worldwide.

Entities: Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20401506 DOI： 10.1007/s10067-010-1457-8

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

12 in total

1. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

Authors: Kelsey M Jordan; J Stewart Cameron; Michael Snaith; Weiya Zhang; Michael Doherty; Jonathan Seckl; Aroon Hingorani; Richard Jaques; George Nuki
Journal: Rheumatology (Oxford) Date: 2007-05-23 Impact factor: 7.580

2. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Authors: M K Reinders; E N van Roon; T L Th A Jansen; J Delsing; E N Griep; M Hoekstra; M A F J van de Laar; J R B J Brouwers
Journal: Ann Rheum Dis Date: 2008-02-04 Impact factor: 19.103

Review 3. Recent advances in the management of gout and hyperuricemia.

Authors: Robert L Wortmann
Journal: Curr Opin Rheumatol Date: 2005-05 Impact factor: 5.006

4. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors: Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245

Review 5. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors: W Zhang; M Doherty; E Pascual; T Bardin; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal: Ann Rheum Dis Date: 2006-05-17 Impact factor: 19.103

Review 6. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors: W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal: Ann Rheum Dis Date: 2006-05-17 Impact factor: 19.103

7. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.

Authors: H R Schumacher; M A Becker; E Lloyd; P A MacDonald; C Lademacher
Journal: Rheumatology (Oxford) Date: 2009-02 Impact factor: 7.580

Review 8. Treating to target: a strategy to cure gout.

Authors: Fernando Perez-Ruiz
Journal: Rheumatology (Oxford) Date: 2009-05 Impact factor: 7.580

9. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.

Authors: M K Reinders; C Haagsma; T L Th A Jansen; E N van Roon; J Delsing; M A F J van de Laar; J R B J Brouwers
Journal: Ann Rheum Dis Date: 2008-07-16 Impact factor: 19.103

10. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Authors: H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge
Journal: Arthritis Rheum Date: 2008-11-15

15 in total

1. Orthopaedic case of the month: medial knee pain in a 69-year-old man.

Authors: Rej S Bhumbra; Monica Khanna; Brendan C Dickson; Peter C Ferguson
Journal: Clin Orthop Relat Res Date: 2010-10-19 Impact factor: 4.176

2. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors: A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal: Rheumatol Int Date: 2013-09-12 Impact factor: 2.631

Review 3. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.

Authors: David S Goldfarb
Journal: Clin J Am Soc Nephrol Date: 2011-07-14 Impact factor: 8.237

4. Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study.

Authors: Mona Alshahawey; Sara M Shaheen; Tamer Elsaid; Nagwa Ali Sabri
Journal: Int Urol Nephrol Date: 2019-08-01 Impact factor: 2.370

5. New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome.

Authors: Tim L Jansen; Dianne Berendsen; Tania O Crisan; Maartje C P Cleophas; Mirian C H Janssen; Leo A B Joosten
Journal: Clin Rheumatol Date: 2014-04-24 Impact factor: 2.980

6. Efficacy and safety of febuxostat in patients with hyperuricemia and gout.

Authors: Ignacio Garcia-Valladares; Tahir Khan; Luis R Espinoza
Journal: Ther Adv Musculoskelet Dis Date: 2011-10 Impact factor: 5.346

Review 7. [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors: U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal: Z Rheumatol Date: 2016-08 Impact factor: 1.372